Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Inflammatory Skin Disease Treatment Identification Study (IDENTITY)

Clinical Trial Details

As the number of available treatments for psoriasis and atopic dermatitis grow, there is a need to find a way to identify which treatment will work best for each person. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment success and/or failure in participants with atopic dermatitis or psoriasis. 

Participants will provide information about their psoriasis or atopic dermatitis, treatments used, and information about how their body responds to the treatments. No changes will be made in the therapy as a result of participating in this study.

There are up to 11 scheduled study visits for this study during a period of 3 years. During these visits, participants may have skiin exams and provide skin samples. A stipend of $50 to cover time and travel is available following each completed visits. 

Information learned from taking part in this study may help other patients in the future. 
Key Eligibility: 
  1. Between the ages of 2 and 85
  2. A diagnosis of either atopic dermatitis or psoriasis in which treatment is recommended
  3. Not exposed to phototherapy or using topical treatments in the 2 weeks prior to enrollment 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Dermatology Research Team
(646) 962-2090
ann9055@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

2109023958

Sponsor:

Castle Biosciences, Inc.

Status

Open to Enrollment

Age Group

Adult , Pediatric

Sponsor